ClinicalTrials.gg
RecruitingNCT07086924Updated Jul 25, 2025

Genetic Variation in TRAF3IP2 (rs13190932)

An interventional study of Methotrexate in Psoriasis and Psoriatic Arthritis, sponsored by South Valley University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-25.

Primary conditionArthritis, PsoriaticRegistry: PsoriasisReclassifiedWhy we changed it
Registry
Psoriasis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Arthritis, Psoriatic
Why
  1. The study's listed conditions name Arthritis, Psoriatic, a narrower term within Psoriasis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by South Valley University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing methotrexate in Arthritis, Psoriatic — 5 open to participants now, 5 under way, 1 of them phase 3. Methotrexate · Arthritis, Psoriatic.

Planned enrollment
9th of 10
50 · median 112
Started
2025
with 2 others
No phase
2 of 10
2 open now
Registered
8th of 10
by date
Lead sponsor
2 of 10
South Valley University

Among the 10 studies testing methotrexate in Arthritis, Psoriatic, this one is the 9th largest by planned enrollment, is one of 3 that started in 2025, is one of 2 with no phase, and was the 8th registered.

Arthritis, Psoriatic

602 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

5 of the 10 studies testing methotrexate in Arthritis, Psoriatic are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About methotrexate

Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 89 Arthritis, Psoriatic studies recruiting now, 52 (58%) set no upper age limit and 28 (31%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing methotrexate in Arthritis, Psoriatic, or all of them as a file.
02

Study summary

Psoriasis is an immune-mediated inflammatory disease that is highly prevalent worldwide, affecting approximately 2-3% of the world population.

It is characterized by red, scaly plaques that can appear on various parts of the body, causing significant physical and psychological burden to affected individuals.

The Pathogenesis of PsA involves a complex interplay of genetic, immunological, and environmental factors.Genetic studies have identified several susceptibility loci, including HLA-Cw6 and IL23R, which are shared with psoriasis. Additionally, the presence of certain alleles, such as HLA-B27, is associated with a more severe disease course and a higher likelihood of axial involvement.

Read the detailed description

Psoriatic arthritis (PsA) is a chronic systemic inflammatory arthritis that involves both peripheral joints and axial skeleton associated with psoriasis. The extra-articular manifestations and comorbidities are also very common. PsA develops in up to 30% of patients with psoriasis, accounting for an estimated 0.3-1.0% of the general population.

The exact aetiopathogenesis of psoriasis is not completely explained. Pathological mechanism involves skin inflammation and hyperproliferation of keratinocytes induced innate and adaptive immune cells. Genetic, immunological and environmental factors are considered the most important aetiologies . Anti-psoriatic topical preparations, such as those containingcorticosteroids or vitamin D3 analogs (usually calcipotriol [Cal]), are the mainstay of treatment of mild-to-moderate plaque psoriasis. Phototherapy and systemic drugs (administered orally or by injection or infusion) are reserved for more severe or refractory psoriasis.

Methotrexate (MTX) has remained the backbone of the treatment for moderate to severe psoriasis ever since its first use nearly half a century ago. Over the years, its high efficacy, low cost, relative ease of administration and usefulness in concomitant psoriatic arthritis have contributed in making MTX the drug of choice in managing severe psoriasis. Although the majority of patients achieve remission of disease activity with MTX, a significant proportion may experience mild and transient adverse effects. From time to time, various guidelines on the use of MTX have correctly and adequately stressed the need for strict monitoring of haematological and hepatic adverse events.

Characterizing psoriatic arthritis (PsA), mainly as an immune-mediated disease that is also affected by barrier proteins. One new PsA and psoriasis-susceptibility gene, TRAF3IP2, codes for the adaptor protein ACT1 (nuclear factor-κB activator 1), a regulator of the NF-κB pathway involved in IL-17 signaling. We were able to identify the common coding variant p.Asp10Aspn as the disease-causing allele with evidence from association findings at single nucleotide polymorphism (SNP) and haplotype levels, as well as binding studies of ACT1 with its interaction partner TRAF6.

TRAF3 is one of the most versatile members of the TRAF family. It is an intracellular protein that primarily acts as an adaptor protein with a large variety of binding partners. TRAF3 interacting protein 2 (TRAF3IP2), also called CIKS or Act1, is a key intermediate in the normal inflammatory response and is involved in the pathogenesis of various autoimmune and inflammatory diseases .Furthermore, TRAF3IP2 is a protein acting downstream of the IL-17 receptor that binds to and stabilizes mRNAs encoding key inflammatory proteins.

03

Conditions studied

  • Psoriasis
  • Psoriatic Arthritis

Browse trials for

04

In context

Arthritis, Psoriatic Reclassified

602 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

This study's planned enrollment of 50 is below the median of 145 across 337 interventional studies indexed under Arthritis, Psoriatic.

Browse Arthritis, Psoriatic studies →

Lead sponsor

South Valley University is the lead sponsor of 154 studies on the registry; 38 are open to participants now.

Compared within Arthritis, Psoriatic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Psoriasis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 -70years .
  • the severity of cutaneous affection is categorized according to PASI score into PASI 7-12 (moderate severity), and PASI > 12 (severe severity). (15)Confirmed diagnosis: Psoriasis vulgaris (PsV) or psoriatic arthritis (PsA) diagnosed by the Dermatologist or the Rheumatologist.
  • Willingness to participate: Signed .
  • Initiating methotrexate (MTX) therapy: For prospective cohort.
  • Availability for follow-up: Patients must be willing and able to attend scheduled visit.

Exclusion criteria

Exclusion Criteria:

  • Patients with other conditions (e.g., rheumatoid arthritis, systemic lupus erythematosus).
  • Pregnancy and lactation.
  • Patients currently undergoing or systemic therapies.
  • Patients with known genetic disorders affect immune system function.
  • Patients with liver or kidney impairment.
  • Patients with allergy or to methotrexate.
  • Patients with active or uncontrolled infections, including chronic infections like tuberculosis.
  • Previous genetic analysis Patients who have previously undergone genetic analysis for the TRAF3IP2 gene polymorphism (rs13190932).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    Group A

    About 30 patients suffering from psoriasis

    Drug: Methotrexate

  • Active comparator
    Group B

    About 10 patients suffering from psoriatic arthritis

    Drug: Methotrexate

  • Experimental
    Group C

    About 10 healthy control group

    Drug: Methotrexate

Interventions

  • Assessing the response of psoriasis and psoriatic arthritis to Methotrexate. and also Assessing the pharmacogenetic association between TRAF3IP2 ( rs13190932 ) gene Polymorphism in psoriatic and psoriatic arthritis patients taking Methotrexate.

    Also known as: Genetic variation in TRAF3IP2

07

What researchers measure

Primary outcomes

  1. Treatment of Psoriasis and Psoriatic arthritis

    Treatment the patients whom suffering from Psoriasis and Psoriatic arthritis and Assessment of clinical improvement to methotrexate therapy according to: PASI score into PASI 50: means 50% reduction in PASI score - an acceptable measure of efficacy for secondary endpoints in psoriasis clinical trials PASI 75: means 75% reduction in PASI score - standard efficacy measure used in most psoriasis clinical studies1 PASI 90: means 90% reduction in PASI score (almost clear skin) PASI 100: means Completely clear skin.

    Time frame: 3 months

  2. Evalaute the effect of treatment with Methotrexate

    Evaluate the effect of treatment with methotrexate therapy (15 mg per week) on the level of serum TRAF3IP2( rs13190932 ) gene Polymorphism on the Participants whom suffering from Psoriasis and Psoriatic arthritis.

    Time frame: 3 months

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2026, 12 months after the start.

Of 67 non-industry interventional studies with no phase under Arthritis, Psoriatic, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 43. This study's planned 12 months is below that.

Counting every sponsor, half of 72 studies reached it within 31 months; a quarter within 13 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2025
First posted
Jul 25, 2025
StartActual
Jun 1, 2025
Primary completionEst.
Jun 1, 2026
CompletionEst.
Jun 10, 2026
Last update
Jul 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07086924
Responsible party
Fawzia Mohamed Abdelzaher Mohamed (Resident of Dermatology, Venereology and Andrology,Faculty of Medicine, South Valley University) — Principal investigator
First posted
Jul 25, 2025
Start date
Jun 1, 2025
Primary completion
Jun 1, 2026 (estimated)
Completion
Jun 10, 2026 (estimated)
Last update
Jul 25, 2025

Study contacts

Fawzia Mohamed Abd Elzaher, MSC
Contact
drfawzia11111995@gmail.com
+201001238064
Soheir Abdel-Hamid Ali, Lecturer
Contact
Soher.abdel-hamed@med.svu.edu.eg
+201066877343
Eisa Mohammed Hegazy, Professor
study chair · Dermatology,Venereology,and Andrology Department,Faculty of Medicine,South Valley University, Egypt

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methotrexate

Start the discussion